Trials & Filings

CEL-SCI Trial in Bosnia Approved

Brings number of countries to 10 in head & neck cancer trial

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

CEL-SCI Corp. has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into its Phase III Head and Neck Cancer clinical trial of investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection). Bosnia and Herzegovina is the 10th country into which CEL-SCI has expanded this global Phase III trial. This also marks the company’s milestone in receiving approval to commence accrual...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters